Abeona Therapeutics Inc. Company Profile
NASDAQ: ABEOHealth CareBiotechnology: Pharmaceutical PreparationsUSD
Market open · Delayed 15 min · as of Oct 8, 2:42 PM ET
Abeona Therapeutics at a glance
Abeona Therapeutics Inc. (NASDAQ: ABEO) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Cleveland, OH. Abeona Therapeutics is led by Dr. Vishwas Seshadri M.B.A., Ph.D. and employs about 226 people. At a market capitalization of $286.5 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0000318306, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Abeona Therapeutics do?
Abeona Therapeutics Inc., a commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States. It develops ZEVASKYN, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa. The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.
Business description based on the company's public filings.
Company information
- Legal name
- Abeona Therapeutics Inc.
- Ticker
- NASDAQ: ABEO
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Vishwas Seshadri M.B.A., Ph.D.
- Employees
- 226
- Headquarters
- 6555 Carnegie Avenue, Cleveland, OH, United States
- Phone
- 646 813 4701
- Website
- abeonatherapeutics.com
- Market cap
- $286.49M
- SEC CIK
- 0000318306
Companies similar to Abeona Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| BIOABioAge Labs Inc. | 6.23 | -0.49% | $285.91M | vs ABEO |
| FULCFulcrum Therapeutics Inc. | 3.74 | +1.77% | $284.97M | vs ABEO |
| RCKTRocket Pharmaceuticals Inc. | 2.65 | +4.34% | $290.35M | vs ABEO |
| LRMRLarimar Therapeutics Inc. | 2.69 | -2.36% | $278.93M | vs ABEO |
| CYPHCypherpunk Technologies Inc. | 2.76 | -9.51% | $297.43M | vs ABEO |
| CATXPerspective Therapeutics Inc. | 2.64 | +7.11% | $300.79M | vs ABEO |
| VNDAVanda Pharmaceuticals Inc. | 4.49 | -1.54% | $271.48M | vs ABEO |
| BBOTBridgeBio Oncology Therapeutics Inc. | 3.39 | -1.60% | $271.39M | vs ABEO |